Alivus Life Sciences Ltd vs Mercury Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 27.2 on March 2025 . This represents a CAGR of 19.36% over 4 yearsThe P/E Ratio of Mercury Laboratories Ltd changed from 14.4 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 16.80% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 13229 crore on March 2025 . This represents a CAGR of 23.84% over 4 yearsThe Market Cap of Mercury Laboratories Ltd changed from ₹ 77.11 crore on March 2021 to ₹ 98.29 crore on March 2025 . This represents a CAGR of 4.97% over 5 years The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The revenue of Mercury Laboratories Ltd for the Dec '25 is ₹ 18.66 crore as compare to the Sep '25 revenue of ₹ 19.8 crore. This represent the decline of -5.76% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The ebitda of Mercury Laboratories Ltd for the Dec '25 is ₹ 2.44 crore as compare to the Sep '25 ebitda of ₹ 2.92 crore. This represent the decline of -16.44% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 18.60% The net profit of Mercury Laboratories Ltd changed from ₹ 0.34 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of 85.24% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Mercury Laboratories Ltd changed from 7.87 % on March 2021 to 13.38 % on March 2025 . This represents a CAGR of 11.20% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Mercury Laboratories Ltd

Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
Subsequently, it converted into Private Limited Company & incorporated in February, 1982.
Later, it converted into Limited Company in 1992 in Maharashtra.
The Company has obtained ISO 9001:2008 registrations.
It is engaged into the manufacturing and export of wide range of Pharmaceutical items.

FAQs for the comparison of Alivus Life Sciences Ltd and Mercury Laboratories Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Mercury Laboratories Ltd?

Market cap of Alivus Life Sciences Ltd is 12,733 Cr while Market cap of Mercury Laboratories Ltd is 90 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Mercury Laboratories Ltd?

The stock performance of Alivus Life Sciences Ltd and Mercury Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Mercury Laboratories Ltd?

As of May 4, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1037.5. On the other hand, Mercury Laboratories Ltd stock price is INR ₹750.0.

How do dividend payouts of Alivus Life Sciences Ltd and Mercury Laboratories Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Mercury Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.